Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study.

Introduction

Older patients with cancer have distinct characteristics of physical, emotional, cognitive, and nutritional function when compared with younger patients. 1 These patients have a decreased capacity for recovery from internal and external stress, and are susceptible to adverse events from cancer treatment. 1 , 2 However, there remains minimal evidence from clinical trials on the efficacy and safety of cancer treatment in older patients. 3 , 4 Therefore, it is challenging to make evidence-based decisions on the use of cytotoxic chemotherapy in older populations.

Geriatric assessment (GA) has been proved to be an objective tool to quantify the overall health status of older populations more comprehensively and precisely. 5 – 7 It has been reported that GA could be associated with life expectancy, compliance of chemotherapy, postoperative mortality risk, and early death. 5 , 6 , 8 , 9 Two prediction tools for chemotherapy toxicity based on GA have been reported. 10 – 12 However, both of these studies were conducted in Western countries. Prevalent cancer types, drug metabolism, nutritional status, and social support are inevitably different according to different countries, races, and cultures. 13 – 17 In addition, ethnic differences in drug metabolism and chemotherapy toxicities are also well established. 18 , 19 Furthermore, the type and number of domains included in GA are diverse between different institutions and societies in clinical practice. 20 Therefore, different studies using GA are needed in Asian countries. In addition, two different prediction tools for chemotherapy toxicity predicted dichotomous outcomes regardless of completed chemotherapy cycles. 10 , 12 In routine clinical practice, information on the occurrence of adverse events in each chemotherapy cycle may be more useful. The cumulative incidence of toxicity may provide additional information since incidence of toxicities increase as the chemotherapy cycle proceeds.

Therefore, we aimed to develop a novel prediction tool to predict chemotherapy toxicity in Asian populations using clinical parameters and GA. The cumulative risk of toxicity was explored in proceeding chemotherapy cycles.

Patients and methods

Study design and participants

The Korean Cancer Study Group (KCSG) study PC13-09 was a prospective, longitudinal, and multicentre cohort study to develop a prediction tool for adverse events ≥ Grade 3 (G3) due to chemotherapy. Between February 2014 and December 2015, 301 patients were enrolled in 17 hospitals affiliated with the KCSG. The primary outcome was defined as occurrence of adverse events ≥ G3. Inclusion criteria included the following: patient ≥70 aged old; candidate for first-line palliative chemotherapy; and patients with histologically confirmed solid tumour. The exclusion criteria included the following: haematologic malignancy such as lymphoma, leukaemia, and multiple myeloma; patient who had a treatment plan to receive monotherapy with biologic agent or targeted agent, concurrent chemoradiotherapy, combination chemotherapy with investigational agents, or monotherapy with oral agents; and recurrent cases during adjuvant chemotherapy. GA was conducted after obtaining informed consent and before first-line chemotherapy. Chemotherapy regimen was chosen at an oncologist’s discretion. The dosing of chemotherapy regimen was recommended as described in the National Comprehensive Cancer Network guideline. Initial dose reduction was permitted based on clinical decision by the investigator. Adverse events were assessed by using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 in each cycle of chemotherapy.

Clinical parameters and GA

Pretreatment baseline measures such as laboratory findings (complete blood cell counts and chemistry), cancer type, stage, and fracture history were recorded. Chemotherapy regimen and dosing were documented. Patients were followed to collect adverse events at the end of each cycle. As in our previous studies, GA consisted of evaluating medical problems, social support, functional status, cognitive status, emotional status, nutritional status, and mobility. 5 – 7 , 21 In brief, comorbidity was measured using the Charlson comorbidity index and was divided into low (0 points), medium (1–2 points), high (3–4 points), and very high (≥5 points) groups according to the original weighting system. 22 Functional status was evaluated using the activities of daily living (ADL) and Korean instrument ADL (K-IADL) scores. 23 – 25 At least one dependency in ADL or K-IADL was categorised as ADL-dependent or IADL-dependent, respectively. Timed Get Up and Go test (TGUG) >20 s was regarded as impaired mobility. 26 Cognitive function was evaluated using Mini Mental Status Examination (MMSE) in the Korean version of the Consortium to Establish a Registry for Alzheimer’s disease Assessment Packet, which was divided into severe cognitive impairment (scores ≤ 16) and mild cognitive impairment (scores 17–24). 27 For depression, Short-Form Geriatric Depression Scale scores of 5–9 and of 10 or more indicated mild depression and severe depression, respectively, (ranging from 0 to 15). 28 In terms of nutritional status, the Mini Nutritional Assessment (MNA) score <17.0 and between 17.0 and 23.5 indicated malnutrition and a risk for malnutrition, respectively. 29 Polypharmacy was evaluated based on number of drugs taken both descriptively and quantitatively. GA was conducted by clinical research coordinators who attended GA workshops to standardise GA and received certificate issued by KCSG.

Development of prediction tool

Variables used to develop a predictive model for chemotherapy toxicity were as follows: clinical parameters such as age, sex, performance status, chemotherapy regimen, initial dose reduction, tumour type; laboratory findings; and all items of each domain in GA. Variables significantly associated with occurrence of adverse events ≥ G3 were identified in univariate analysis using a Cox proportional-hazards model. For developing a prediction tool, selected variables were assigned a score according to hazard ratios for adverse events ≥ G3 in a multivariate analysis of the Cox proportional-hazards model. Compared with actual incidence, the best prediction model was selected based on c -statistic.

Statistical analysis

Assuming an incidence of 45% for adverse events ≥ G3 and drop-out rate of 10%, at least 200 patients were needed based on the incidence of adverse events ≥ G3 estimated in the population by Harrell’s guideline. The protocol was amended for robust significance to include 300 patients. The Cox proportional-hazards model was used to identify variables related with occurrence of adverse events ≥ G3. Multivariate models included variables that showed significance in univariate analysis with p < 0.05. The discriminatory ability of the prediction tool was evaluated using the c -statistic. Predicted probabilities for each cycle were generated based on the risk scores. This study was approved by the institutional review board of each participating centre and the KCSG (KCSG PC13-09). This study was registered with Clinical Research Information Service (WHO ICTRP number: KCT0001071). Patients completed the informed consent process.

Results

Patient characteristics

We enrolled 301 patients aged ≥70 years in this trial. Baseline patient characteristics, including demographics, chemotherapy, laboratory findings, and GA are shown in Tables 1 and 2 . Forty-two patients (14.0%) were 80 years or older. Most patients had good performance status with Eastern Cooperative Oncology Group (ECOG) ≤ 1 (81.4%) and stage IV (97.0%). Median body mass index (BMI) was 22.5 (range 14.0–31.2). The most common cancer types were colorectal cancer (28.9%), lung cancer (24.6%), hepato-biliary-pancreatic cancer (22.3%), and stomach cancer (10.6%). In 177 patients (58.8%), initial dose reduction was applied at the first cycle. Table 1 Baseline patient characteristics, clinical parameters Variable N = 301 (%) Median age (range) 70–79 259 (86.0) 80–89 40 (13.3) 90–100 2 (0.7) Sex Male 208 (69.1) Female 93 (30.9) ECOG performance 0 39 (13.0) 1 206 (68.4) 2 52 (17.3) 3/4 4 (1.3) Cancer type Colorectal cancer 87 (28.9) Lung 74 (24.6) Hepato-biliary-pancreatic 67 (22.3) Stomach 32 (10.6) Urinary tract cancer (including prostate) 15 (5.0) Head and neck 10 (3.3) Breast 4 (1.3) Gynaecological 4 (1.3) Oesophageal cancer 3 (1.0) Sarcoma 2 (0.7) Melanoma 2 (0.7) Thymoma 1 (0.3) Stage III 7 (2.3) IV 292 (97.0) Unknown 2 (0.7) Regimen Monochemotherapy 24 (8.0) Combination chemotherapy 274 (91.0) Unknown 3 (1.0) Dose reduction (initial) Yes 177 (58.8) No 119 (39.5) Unknown 5 (1.7) Haemoglobin, g/dL ≥10 (female), ≥11 (male) 229 (76.1) <10 (female), <11 (male) 72 (23.9) Neutrophil-lymphocyte ratio a ≤2.9 151 (50.2) >2.9 150 (49.8) Platelet, ×10 3 /µL a ≥248 153 (50.8) <248 148 (49.2) Protein, g/dL a ≥6.7 152 (50.5) <6.7 149 (49.5) Creatinine clearance rate a ≥56.6 150 (49.8) <56.6 151 (50.2) Na, mmol/L ≥135 233 (77.4) <135 68 (22.6) Albumin, g/dL ≥3.6 195 (64.8) <3.6 106 (35.2) Cholesterol, mg/dL a ≥150 142 (47.2) <150 138 (45.8) Unknown 21 (7.0) C-reactive protein, mg/dL a ≥1.1 150 (49.8) <1.1 142 (47.2) Unknown 9 (3.0) ECOG Eastern Cooperative Oncology Group. a The median value of neutrophil-lymphocyte ratio, platelet, protein, creatinine clearance rate, cholesterol, and c-reactive protein was 2.9, 248 × 10 3 /µL, 6.7 g/dL, 56.6, 150 mg/dL, and 1.1 mg/dL, respectively Table 2 Baseline patient characteristics, geriatric assessment Variable N = 301 (%) Live alone Yes 42 (14.0) No 259 (86.0) Live with spouse Yes 211 (70.1) No 90 (29.9) Previous fracture history Yes 12 (4.0) No 289 (96.0) Comorbidity (Charlson risk index) Low (0 points) 157 (52.2) Medium (1–2 points) 114 (37.9) High (3–4 points) 28 (9.3) Very high (≥5 points) 2 (0.7) Activity of daily living Independent 215 (71.4) Dependent 86 (28.6) Instrumental activity daily of living Independent 177 (58.8) Dependent 124 (41.2) Cognitive function (MMSE-KC) Intact (25–30) 134 (44.5) Mild impairment (17–24) 137 (45.5) Severe impairment (≤16) 30 (10.0) Depression (SGDS) Intact (<5) 167 (55.5) Mild depression (10 ≥ 5) 92 (30.6) Severe depression) (≥10) 40 (13.3) Unknown 2 (0.7) Nutritional status (MNA) Normal (≥24) 70 (23.3) Risk of malnutrition (17 ≤ 24) 171 (56.8) Malnutrition (<17) 59 (19.6) Unknown 1 (0.3) Mobility (TGUG) Intact 235 (78.1) Impaired 25 (8.3) Unknown or not capable 41 (13.6) MMSE-KC Mini Mental Status Examination in the Korean version of the Consortium to Establish a Registry for Alzheimer’s disease Assessment Packet, SGDS Short-Form Geriatric Depression Scale, MNA Mini Nutritional Assessment, TGUG Timed Get Up and Go test

In terms of GA, 14.0% and 70.1% of patients lived alone and with a spouse, respectively. The median number of medications taken was 5. According to Charlson comorbidity index, most patients had low or medium risks of comorbidity (52.2% and 37.9%, respectively). ADL and IADL were dependent in 28.6% and 41.2% of patients, respectively. Mild and severe impairment of cognitive function by MMSE were detected in 45.5% and 10.0% of patients, respectively. Mild and severe depression occurred in 30.6% and 13.3% of participants, respectively. The risk of malnutrition and having malnutrition, as assessed by MNA and impaired mobility by TGUG > 20 s, were identified in 56.8%, 19.6%, and 8.3%, respectively. In laboratory findings, low haemoglobin (Hb) level (Hb < 10 g/dL in female and Hb < 11 g/dL in male), hyponatremia (<135 mmol/L), and hypoalbuminemia (<3.6 g/dL) were shown in 23.9%, 22.6%, and 35.2% of patients, respectively.

Chemotherapy and adverse events

The median number of chemotherapy cycles given was four in this study (range 25–75%, 2–7 cycles). On the discretion of the physician and according to tumour type, various chemotherapy regimens were administered in the enrolled patients (Supplementary Table 1 ). Five patients were not followed up for chemotherapy and adverse events. In all, 274 patients (91.0%) received combination chemotherapy and 24 patients (8.0%) received monochemotherapy. During the study period, 53.8% of patients experienced adverse events ≥ G3. Haematologic and non-haematologic adverse events ≥ G3 occurred in 37.2% and 37.9% of patients, respectively. By completion of the first chemotherapy cycle, 19.9% of patients experienced adverse events ≥ G3 (12.0% haematologic and 12.0% non-haematologic adverse events). The most common haematologic adverse events ≥ G3 were neutropaenia (28.2%), anaemia (11.6%), thrombocytopaenia (8.3%), and febrile neutropaenia (4.3%). The most common non-haematologic adverse events ≥ G3 were fatigue (7.6%), anorexia (6.3%), abdominal pain (5.0%), nausea (4.7%), and diarrhoea (3.3%) (Table 3 ). G5 adverse events occurred in 14 patients (4.0%), which consisted of dyspnea (3 patients), sepsis (3 patients), febrile neutropaenia (1 patient), ileus (1 patient), lung infection (1 patient), multi-organ failure (1 patient), peritoneal infection (1 patient), pneumonitis (1 patient), thromboembolic event (1 patient), and supraventricular tachycardia (1 patient). In all, 6 of 14 G5 adverse events were considered to be related with treatment according to the investigator. Table 3 Common adverse events ≥ G3 Variable N (%) Haematologic adverse events, ≥G3 Neutropaenia 85 (28.2) Anaemia 35 (11.6) Thrombocytopaenia 25 (8.3) Febrile neutropaenia 13 (4.3) Non-haematologic adverse events, ≥G3 Fatigue 23 (7.6) Anorexia 19 (6.3) Abdominal pain 15 (5.0) Nausea 14 (4.7) Diarrhoea 10 (3.3)

Predictive variables associated with occurrence of adverse events ≥ G3

Predictive variables were selected in the univariate analysis, which included clinical parameters such as age, sex, ECOG performance status, cancer type, chemotherapy-related variables, and each item from every domain in the GA. Six variables showed a significant association with incidence of adverse events ≥ G3. Six variables included serum protein < 6.7 g/dL, initial full-dose chemotherapy, suffering from psychological stress or acute disease in the past 3 months, water consumption of less than three cups per day, not being able to obey command of “take a piece of paper in your hand”, and self-perception of “not in good health” (Table 4 ). Table 4 Selection of individual variables associated with occurrence of adverse events ≥ G3 Variable Prevalence ≥G3, adverse event incidence Univariate N = 296 a % N = 162 % HR (95% CI) p -value Protein ≥6.7 147 49.7 72 49.0 1 <6.7 149 50.3 90 60.4 1.43 (1.05–1.95) 0.024 Initial dose reduction Yes 177 59.8 83 46.9 1 No 119 40.2 79 66.4 1.66 (1.21–2.26) 0.002 Has suffered psychological stress or acute disease in the past 3 months? No 129 43.6 58 45.0 1 Yes 166 56.1 104 62.7 1.49 (1.08–2.05) 0.016 How much fluid (water, juice, coffee, tea, milk…) is consumed per day? More than 3 cups 235 79.4 122 51.9 1 Less than 3 cups 60 20.3 40 66.7 1.62 (1.13–2.33) 0.009 Obey command: “take a piece of paper in your hand” Accomplishment 242 81.8 125 51.7 1 No accomplishment 49 16.6 34 69.4 1.49 (1.02–2.19) 0.039 Health perception As good or better 181 61.1 92 50.8 1 Not as good 115 38.9 70 60.9 1.42 (1.04–1.94) 0.028 a Of 301 patients, 5 patients were not followed for chemotherapy and adverse events

Developing a prediction tool for occurrence of adverse events ≥ G3

Several different models were developed based on the results in the univariate/multivariate analyses. Those six variables that showed significance in the univariate analysis were included in the multivariate analysis, with four of them remaining significant in the all multivariate models: serum protein < 6.7 g/dL; initial full-dose chemotherapy; suffering from psychological stress or acute disease in the past 3 months; and water consumption of less than three cups per day. Model 1 consists of these four variables. Models 2 and 3 were developed by adding another variable to model 1 for up to five variables. Model 4 consisted of all variables that were significant in the univariate analysis. In each model, scores for each variable were assigned based on hazard ratio in the multivariate analysis (Table 5 ). Table 5 Modeling of prediction tool Variable Model 1 Model 2 Model 3 Model 4 Multivariate Multivariate Multivariate Multivariate HR (95% CI) p -value Score HR (95% CI) p -value Score HR (95% CI) p -value Score HR (95% CI) p -value Score Protein ≥6.7 1 1 1 1 <6.7 1.44 (1.05–1.97) 0.024 1 1.38 (1.01–1.90) 0.047 1 1.42 (1.03–1.94) 0.032 1 1.35 (0.98–1.86) 0.067 1 Initial dose reduction Yes 1 1 1 1 No 1.74 (1.27–2.38) <0.001 2 1.75 (1.28–2.40) <0.001 2 1.72 (1.26–2.35) <0.001 2 1.72 (1.25–2.37) <0.001 2 Has suffered psychological stress or acute disease in the past 3 months? No 1 1 1 1 Yes 1.47 (1.06–2.03) 0.016 1 1.47 (1.06–2.05) 0.022 1 1.38 (0.98–1.94) 0.063 1 1.38 (0.97–1.96) 0.071 1 How much fluid (water, juice, coffee, tea, milk…) is consumed per day? More than 3 cups 1 1 1 1 Less than 3 cups 1.57 (1.09–2.26) 0.015 2 1.55 (1.06–2.25) 0.023 2 1.58 (1.10–2.28) 0.015 2 1.56 (1.07–2.27) 0.021 2 Obey command: “take a piece of paper in your hand” Accomplishment 1 1 No accomplishment 1.32 (0.90–1.95) 0.162 1 1.33 (0.90–1.97) 0.147 1 Health perception As good or better 1 1 Not as good 1.27 (0.87–1.70) 0.246 1 1.22 (0.87–1.71) 0.243 1

To select the best model for the prediction of adverse events ≥ G3 with the highest discriminatory ability, c -statistics were calculated. Model 4 showed the highest mean c -statistic (0.646, Supplementary Table 2 ). Finally, model 4, consisting of six variables, was confirmed as the most accurate prediction tool for occurrence of adverse events ≥ G3 (Supplementary table 3 ).

Prediction tool for occurrence of adverse events ≥ G3

The predication tool indicated scores ranging 0–8 point. Patients with higher scores had more risk for adverse events ≥ G3. Score distribution is indicated in supplementary figure 1 . Risk groups were classified according to score as low risk (0, 1), medium-low risk (2, 3), medium-high risk (4, 5), and high risk (6, 7, 8). Of patients classified by risk groups, 61 (21.0%), 143 (49.3%), 66 (22.8%), and 20 (6.9%) were in low, medium-low, medium-high, and high-risk groups, respectively. In each risk group, predicted cumulative incidence of adverse events ≥ G3 increased with the chemotherapy cycle number. In the low-risk group, predicted cumulative incidence of adverse events ≥ G3 was 9.9%, 19.2%, 26.1%, 32.8%, and 35.9% in cycle 1, cycle 2, cycle 3, cycle 4, and cycle 5, respectively. In the medium-low-risk group, predicted cumulative incidence of adverse events ≥ G3 was 16.0%, 30.1%, 39.8%, 48.7%, and 52.6% in cycle 1, cycle 2, cycle 3, cycle 4, and cycle 5, respectively. In the medium-high-risk group, predicted cumulative incidence of adverse events ≥ G3 was 24.4%, 43.6%, 55.6%, 65.5%, and 69.7% in cycle 1, cycle 2, cycle 3, cycle 4, and cycle 5, respectively. In the high-risk group, predicted cumulative incidence of adverse events ≥ G3 was 37.0%, 60.9%, 73.4%, 82.3%, and 85.5% in cycle 1, cycle 2, cycle 3, cycle 4, and cycle 5, respectively. In the same cycle, predicted cumulative incidence of adverse events ≥ G3 was also discriminated according to risk group (Fig. 1 ). Fig. 1 Actual incidence ( a ) and predicted incidence ( b ) of adverse events ≥ G3 according to the risk group and cycle

Discussion

From this prospective longitudinal multicentre study, we developed a novel prediction tool to identify those patients at risk for adverse events ≥ G3 in older patients undergoing first-line chemotherapy. This prediction tool consisted of six variables from clinical parameters and GA conducted pre-chemotherapy, with an ability to identify four risk groups (low, medium-low, medium-high, and high), which quantified cumulative risk rates of adverse events ≥ G3 from the first to the fifth cycle.

There are two established and validated prediction tools for severe chemotherapy toxicity (G4 haematologic toxicity and G3/4 non-haematologic toxicity; G3-5 chemotherapy-related toxicity). 10 – 12 Nevertheless, our prediction tool has distinct features in terms of study population, primary outcome, and modeling methods as compared to previous studies.

This study population consisted of Koreans and patients initiating first-line chemotherapy. Previous studies were conducted in hospitals of the United States with most patients of Caucasian race. Toxicity profiles from chemotherapy are reported to be different by geographic regions due to ethnic differences in drug metabolism, nutritional status, social support, and medical culture. 19 , 30 For example, Asians showed more frequent occurrence of febrile neutropaenia (18.6% vs 7.1%), edema (26.1% vs 5.4%), myalgia (42.3% vs 14.7%), and decreased appetite (47.0% vs 19.1%) in the phase III CLEOPATRA trial. 30

Moreover, our study population showed a lower median BMI (22.5 vs. 25.9 in a previous study conducted in the United States), 10 included more gastrointestinal cancer types, more frequent dose reductions (58.8% vs 24.0%) as compared with previous study. The different population characteristics and tolerances to chemotherapy justify the development chemotherapy prediction tools developed in Asian populations. Furthermore, patients in this study who were initiating only first-line chemotherapy were enrolled in contrast with previous studies, which allowed prior palliative chemotherapy. Vulnerability for chemotherapy could be different across chemotherapy lines. With additional lines of chemotherapy, chemotherapy toxicity may occur more frequently. It would be more ideal to include homogenous populations in terms of number of chemotherapy lines to develop precise chemotherapy toxicity prediction tool.

Regarding the primary outcome, in contrast with other studies using treatment-related toxicity, our study used adverse event as the primary measure regarding outcome. It is often difficult to determine the causality of adverse events in clinical practice. In view of older patients with cancer and their family members, events itself during chemotherapy are important regardless of causality. Therefore, adverse event is a suitable outcome measure in this study with older patients with cancer.

In terms of modeling methods, our prediction models were developed using the Cox proportional-hazards model, in which applied chemotherapy cycles and cycle with first adverse event ≥ G3 were incorporated. Therefore, cumulative incidence of adverse event ≥ G3 could be suggested on the contrary to generating just dichotomous outcomes in previous studies. This point is important because incidence of adverse events increase inevitably with proceeding of chemotherapy cycles and most patients recover from adverse event ≥ G3 and continue the next cycle. In our study, 45% of patients in the high-risk group were expected to experience adverse events ≥ G3 during the first cycle. However, almost all patients in the high-risk group were expected to experience adverse events ≥ G3 within fourth cycle. Meanwhile, no more than 30% of patients in the low-risk group were expected to have adverse events ≥ G3 as the cycles proceeded. This information might be valuable to decide and discuss chemotherapy application with older patient with cancer and their family members.

Finally, our prediction tool can utilise a questionnaire of only six questions, which would allow for a simple clinical application in busy oncology clinics. Six questions were related to nutritional status (two questions), recent illness (one question), chemotherapy dosing (one question), cognitive function (one question), and self-estimation for health status (one question). These components were reported as important factors in previous studies associated with geriatric outcome. 6 , 10 , 12 , 21 In previous studies for the prediction of chemotherapy toxicity, chemotherapy dosing, nutritional status, and cognitive function were also included. 10 , 12 Our prediction tool suggested cumulative incidence of adverse events ≥ G3 in each cycle of first-line chemotherapy with a mean c -statistic of 0.646 to predict adverse events ≥ G3, which is comparable to discriminative power found in previous studies. 10 – 12

There are some limitations to this study. First, the applied chemotherapy regimens and cancer types were heterogeneous. It would be ideal to conduct this study in a specific tumour type, being treated with a specific chemotherapy regimen. However, our study aimed to determine common geriatric factors that affect the occurrence of adverse events ≥ G3. Compared with previous studies, only patients who would receive first-line chemotherapy were enrolled for a more homogenous study population. Second, G2 adverse events are also important in vulnerable older patients with cancer who are receiving chemotherapy. Hospitalisation, laboratory abnormality or symptoms etc. to stop chemotherapy, and mortality during chemotherapy could be a good outcome measure. However, these measures are mostly covered in adverse events ≥ G3, which were defined as the primary outcome in this study. Third, this study was performed in Korean patients and patients with first-line chemotherapy, but external validation in different populations or other Asian countries should be conducted. Fourth, in this study population, the risk scores of previous tools could not be calculated due to discrepancy in domains used in GA across studies. Direct comparison of efficacy of this tool with previous tools could not be performed. This prediction tool was designed in different population from previous studies, such as clinically homogeneous and Asian population. Furthermore, cumulative incidence showed in our prediction tool could give another information to clinic practice. Therefore, it would be worth to develop this tool regardless of comparison of efficacy with previous tools.

We developed simple, six-item novel prediction tool for adverse events ≥ G3, which would be easier to use in daily practice and which could provide patients and physicians information to plan chemotherapy in an Asian population. In high-risk patients, a high incidence of adverse events should be anticipated, and preventive and proactive measures should be administered. In other hands, active chemotherapy could be encouraged for patients in the low-risk group. Future studies are needed to evaluate geriatric intervention in high-risk patients to promote the safe use of chemotherapy in older patients with cancer.

Electronic supplementary material

supplementary tables figure

Electronic supplementary material

Supplementary information is available for this paper at 10.1038/s41416-018-0037-6.

Acknowledgements

We are grateful to Hyun Jung Yoo R.N., Si Young Park R.N. (geriatric nurses in Seoul National University Bundang Hospital), and Prof. Myung Sook Park (Department of Nursing, Konkuk University, Chungju, Korea) who helped with geriatric assessment workshops, and Keum Sung Lim (data manager) and Mi Jin Yang (clinical research associate in KCSG data center) who helped to collect and manage data.

This study was supported by grants from the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (study no: 1320370).

Competing interests

The authors declare no competing interests.

References

1. Muss HB Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience J. Clin. Oncol. 2007 25 3699 3704 10.1200/JCO.2007.10.9710 17704418

2. Hurria A Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers J. Clin. Oncol. 2008 26 5386 5392 10.1200/JCO.2008.17.6891 18955446 PMC2651077

3. Autier P Age at cancer diagnosis and interpretation of survival statistics Lancet Oncol. 2016 17 847 848 10.1016/S1470-2045(16)30048-1 27237615

4. Kornblith AB Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials Cancer 2002 95 989 996 10.1002/cncr.10792 12209681

5. Jung HW Multidimensional Geriatric Prognostic Index, based on a geriatric assessment, for long-term survival in older adults in Korea PLoS ONE 2016 11 e0147032 10.1371/journal.pone.0147032 26771562 PMC4714804

6. Kim JW The early discontinuation of palliative chemotherapy in older patients with cancer Support. Care Cancer 2014 22 773 781 10.1007/s00520-013-2033-y 24287502

7. Kim YJ Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy J. Cancer Res. Clin. Oncol. 2011 137 839 847 10.1007/s00432-010-0945-1 20820804 PMC11828243

8. Kim SW Multidimensional frailty score for the prediction of postoperative mortality risk JAMA Surg. 2014 149 633 640 10.1001/jamasurg.2014.241 24804971

9. Soubeyran P Predictors of early death risk in older patients treated with first-line chemotherapy for cancer J. Clin. Oncol. 2012 30 1829 1834 10.1200/JCO.2011.35.7442 22508806

10. Extermann M Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score Cancer 2012 118 3377 3386 10.1002/cncr.26646 22072065

11. Hurria A Validation of a prediction tool for chemotherapy toxicity in older adults with cancer J. Clin. Oncol. 2016 34 2366 2371 10.1200/JCO.2015.65.4327 27185838 PMC5321104

12. Hurria A Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J. Clin. Oncol. 2011 29 3457 3465 10.1200/JCO.2011.34.7625 21810685 PMC3624700

13. Kagawa-Singer M Dadia AV Yu MC Surbone A Cancer, culture, and health disparities: time to chart a new course? Ca Cancer J. Clin. 2010 60 12 39 10.3322/caac.20051 20097836

14. Lannin DR Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer JAMA 1998 279 1801 1807 10.1001/jama.279.22.1801 9628711

15. Shim EJ Health-related quality of life in breast cancer: a cross-cultural survey of German, Japanese, and South Korean patients Breast Cancer Res. Treat. 2006 99 341 350 10.1007/s10549-006-9216-x 16685589

16. Wellisch D An exploratory study of social support: a cross-cultural comparison of Chinese-, Japanese-, and Anglo-American breast cancer patients Psychooncology 1999 8 207 219 10.1002/(SICI)1099-1611(199905/06)8:3<207::AID-PON357>3.0.CO;2-B 10390733

17. Ferlay J Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int. J. Cancer 2015 136 E359 386 10.1002/ijc.29210 25220842

18. O’Donnell PH Dolan ME Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy Clin. Cancer Res. 2009 15 4806 4814 10.1158/1078-0432.CCR-09-0344 19622575 PMC2774468

19. Hasegawa Y Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials J. Thorac. Oncol. 2011 6 1881 1888 10.1097/JTO.0b013e31822722b6 21841503

20. Wildiers H International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer J. Clin. Oncol. 2014 32 2595 2603 10.1200/JCO.2013.54.8347 25071125 PMC4876338

21. Kim JW A novel geriatric screening tool in older patients with cancer: the Korean Cancer Study Group Geriatric Score (KG)-7 PLoS ONE 2015 10 e0138304 10.1371/journal.pone.0138304 26401951 PMC4581840

22. Charlson ME Pompei P Ales KL MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J. Chronic Dis. 1987 40 373 383 10.1016/0021-9681(87)90171-8 3558716

23. Mahoney FI Barthel DW Functional evaluation: the Barthel Index Md. State Med. J. 1965 14 61 65 14258950

24. Won CW Rho YG Duk SW Lee YS The validity and reliability of Korean Instrumental Activities of Daily Living (K-IADL) scale J. Korean Geriatr. Soc. 2002 6 273 280

25. Won CW The development of Korean Activities of Daily Living (K-ADL) and Korean Instrumental Activities of Daily Living (K-IADL) scale J. Korean Geriatr. Soc. 2002 6 107 120

26. Podsiadlo D Richardson S The timed “Up & Go”: a test of basic functional mobility for frail elderly persons J. Am. Geriatr. Soc. 1991 39 142 148 10.1111/j.1532-5415.1991.tb01616.x 1991946

27. Lee DY The prevalence of dementia in older people in an urban population of Korea: the Seoul study J. Am. Geriatr. Soc. 2002 50 1233 1239 10.1046/j.1532-5415.2002.50310.x 12133018

28. Bae JN Cho MJ Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients J. Psychosom. Res. 2004 57 297 305 10.1016/j.jpsychores.2004.01.004 15507257

29. Vellas B The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients Nutrition 1999 15 116 122 10.1016/S0899-9007(98)00171-3 9990575

30. Swain SM Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA Oncologist 2014 19 693 701 10.1634/theoncologist.2014-0033 24869931 PMC4077449